IRCT20210519051345N33招募中Unknown
In vivo bioequivalence study of Gabapentine 300 mg capsule manufactured by Ani Darman Co. compared with innovator product
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18-59 years)
排除标准
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
已完成
不适用
Bioequivalence study of Gabapentin 300 mg capsules in 24 healthy male under fasting conditionsIRCT20180620040164N24Actoverco Pharmaceutical Co.24
招募中
不适用
Bioequivalence study of Gabapentin 300 mg Capsule in 24 healthy male under fasting conditionsIRCT20180620040164N16Dorsa Pharmaceutical Co.26
招募中
不适用
Bioequivalence study of Gabapentin 300 mg CapsuleBioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers.IRCT20220111053692N5Teb Mofid Nikan Pharmaceutical Company24
已完成
3 期
Bioequivalence study of gabapentin 300 mg capsule in Thai healthy volunteers-Thai healthy male and female subjects-Aged 18 †50 years -BMI were within 18ᆭ kg/m2-Good health confirming by physical and clinicaBioequivalencePharmacokineticGabapentinTCTR20170127001Ratchadapisek Sompoj Fund, Chulalongkorn University24
已完成
不适用
Comparative study on the bioequivalence of two different gabapentin 300mg formulations (Sobhan daru & reference) in 24 iranian volunteersHealth and normal volunteers.--IRCT201511058022N3Sobhan Daru pharmaceutical company24